ClinicalTrials.gg
CompletedNCT05656027CLARITY 1Updated May 13, 2026Results posted

Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

A Phase 3 interventional study of Aceclidine+Brimonidine combination ophthalmic solution and Aceclidine ophthalmic solution in Presbyopia, Refractive Error and Eye Diseases, sponsored by LENZ Therapeutics, Inc. Completed at 25 sites in United States. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by LENZ Therapeutics, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
469
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Presbyopia with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Presbyopia · United States.

Enrollment
7th of 120
469 · median 75
Started
2022
with 18 others
Phase 3
20 of 131
1 open now
Registered
92nd of 131
by date
Lead sponsor
8 of 131
LENZ Therapeutics, Inc

Among the 131 studies in Presbyopia with a site in United States, this one is the 7th largest by enrollment of the 120 interventional ones that give a count, is one of 19 that started in 2022, is one of 20 in phase 3, and was the 92nd registered.

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

Browse Presbyopia studies →

Open to participants now

8 of the 131 studies in Presbyopia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Presbyopia studies recruiting now, 7 (39%) set no upper age limit and 9 (50%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Presbyopia with a site in United States, or all of them as a file.
02

Study summary

Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.

Read the detailed description

Phase 3 study to evaluate the safety and effectiveness of LNZ101 compared with LNZ100 and Brimonidine for the treatment of Presbyopia.

03

Conditions studied

  • Presbyopia
  • Refractive Error
  • Eye Diseases
  • Near Vision

Keywords

  • Pharmaceutical Solutions
  • Eye Drops
  • CLARITY
  • Presbyopia
  • Ophthalmic Solutions
  • Miotics
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able and willing to provide written and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed;
  2. Be able and willing to follow all instructions and attend all study visits;
  3. Be 45-75 years of age of either sex and any race or ethnicity at Visit 1;
  4. Have +1.00 to -4.00 diopter (D) of sphere calculated in minus cylinder (so that spherical equivalent (SE) results in myopia no more severe than -4.00 D MRSE) in both eyes determined by manifest refraction documented at Visit 1;
  5. Have ≤2.00 D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1;
  6. Be presbyopic as determined at Visit 1

Exclusion criteria

Exclusion Criteria:

Subjects must not:

  1. Be a female of who is currently pregnant, nursing, or planning a pregnancy;
  2. Have known or sensitivity to the use of any of the study medications or their components;
  3. Have an active ocular infection at Visit 1 or at Visit 2 (bacterial, viral, or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation in either eye;
  4. Have moderate or severe dry eye defined as total central corneal fluorescein staining in either eye at Visit 1;
  5. Have abnormal lens findings including early lens changes in either eye during dilated slit lamp biomicroscopy and fundus exam documented within 3 months of Visit 1 or at Visit 1;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
469 participants (actual)

Study arms

  • Experimental
    Aceclidine + Brimonidine (LNZ101) dosed bilaterally

    LNZ101 (Aceclidine /Brimonidine) ophthalmic solution

    Drug: Aceclidine+Brimonidine combination ophthalmic solution

  • Experimental
    Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally

    LNZ100 (Aceclidine) ophthalmic solution

    Drug: Aceclidine ophthalmic solution

  • Experimental
    Brimonidine ophthalmic solution dosed bilaterally

    Brimonidine ophthalmic solution

    Drug: Brimonidine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision

    Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision on Day 1

    Time frame: 3 hours post-treatment in the study eye on Day 1

07

Results

Posted Feb 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneAceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic Solution
Started156157156
Completed144150148
Not completed1278
Withdrew: Adverse event400
Withdrew: Withdrawal by subject755
Withdrew: Left after installation100
Withdrew: Lost to follow-up013
Withdrew: Prohibited medication used during study participation010

Outcome measures

PrimaryPercentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision

Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision on Day 1

Time frame:
3 hours post-treatment in the study eye on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision
percentage of participantsAceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic Solution
Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision48.68 (40.823 to 56.547)64.5 (57.076 to 71.920)11.49 (6.515 to 16.464)
Statistical analysis
  • Aceclidine + Brimonidine (LNZ101) · Generalized Estimating Equation (GEE) · p = <0.0001 · Odds ratio (or): 7.52
  • Aceclidine Ophthalmic Solution (LNZ100) · Generalized Estimating Equation (GEE) · p = <0.0001 · Odds ratio (or): 14.55

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aceclidine + Brimonidine (LNZ101)0/156 (0%)3/156 (1.9%)73/156 (46.8%)
Aceclidine Ophthalmic Solution (LNZ100)0/157 (0%)0/157 (0%)53/157 (33.8%)
Brimonidine Ophthalmic Solution0/156 (0%)0/156 (0%)25/156 (16%)
Most frequent serious events
Most frequent serious events
EventAceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic Solution
Ocular Treatment-Emergent Serious Adverse EventsEye disorders1/1560/1570/156
Non-Ocular Treatment-Emergent Serious Adverse EventInjury, poisoning and procedural complications1/1560/1570/156
Non-Ocular Treatment-Emergent Serious Adverse EventMusculoskeletal and connective tissue disorders1/1560/1570/156
Most frequent other events
Most frequent other events
EventAceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic Solution
Instillation Site IrritationGeneral disorders31/15630/15710/156
Visual ImpairmentEye disorders28/15616/1570/156
Vision blurredEye disorders6/1565/15715/156
Ocular HyperaemiaEye disorders8/1567/1570/156

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic SolutionTotal
Mean56.2 ± 6.5555.3 ± 6.0754.9 ± 6.4555.5 ± 6.37
Sex: Female, Male
Sex: Female, Male(Participants)Aceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic SolutionTotal
Female9910999307
Male574857162
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic SolutionTotal
Hispanic or Latino553647138
Not Hispanic or Latino101121109331
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aceclidine + Brimonidine (LNZ101)Aceclidine Ophthalmic Solution (LNZ100)Brimonidine Ophthalmic SolutionTotal
American Indian or Alaska Native0213
Asian710825
Native Hawaiian or Other Pacific Islander0011
Black or African American1261028
White134138135407
More than one race1012
Unknown or Not Reported2103
08

Study locations

25 sites
  • Site #106
    Chandler, Arizona 85224, United States
  • Site #121
    Mesa, Arizona 85202, United States
  • Site #122
    Phoenix, Arizona 85032, United States
  • Site #124
    Phoenix, Arizona 85053, United States
  • Site #128
    Scottsdale, Arizona 85260, United States
  • Site #125
    Sun City, Arizona 85351, United States
  • Site #130
    Azusa, California 91702, United States
  • Site #110
    Garden Grove, California 92843, United States
  • Site #101
    Glendale, California 91204, United States
  • Site #129
    Newport Beach, California 92663, United States
  • Site #107
    Petaluma, California 94954, United States
  • Site #126
    Rancho Cordova, California 95670, United States
  • Site #111
    Santa Barbara, California 93105, United States
  • Site #109
    Littleton, Colorado 80120, United States
  • Site #102
    Mt. Dora, Florida 32757, United States
  • Site #118
    Rock Island, Illinois 61201, United States
  • Site #127
    Overland Park, Kansas 66210, United States
  • Site #108
    Pittsburg, Kansas 66762, United States
  • Site #131
    Rochester, New York 14618, United States
  • Site #104
    Fargo, North Dakota 58103, United States
  • Site #103
    Kingston, Pennsylvania 18704, United States
  • Site #116
    Memphis, Tennessee 38104, United States
  • Site #112
    Smyrna, Tennessee 37167, United States
  • Site #119
    San Antonio, Texas 78229, United States
  • Site #123
    San Antonio, Texas 78229, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Dec 2023, 11 months.

Results were first posted in Feb 2026, 2 years 2 months after primary completion. A results delay was requested in Dec 2024.

Of 19 phase 3 interventional studies under Presbyopia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 11. This study's 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Dec 19, 2022
StartActual
Dec 19, 2022
Primary completionActual
Dec 15, 2023
CompletionActual
Jan 25, 2024
Results delay requested
Dec 12, 2024
Results first posted
Feb 25, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05656027
Lead sponsor
LENZ Therapeutics, Inc
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Dec 19, 2022
Primary completion
Dec 15, 2023
Completion
Jan 25, 2024
Results posted
Feb 25, 2026
Last update
May 13, 2026

Study contacts

Kris Gambelin, BS
study director · LENZ Therapeutics, Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aceclidine · Brimonidine

Start the discussion